{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294936","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.609940+00:00","generated_at":"2026-06-07T12:59:10.783566+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MindMed Phase 2b MM-120 in GAD meets primary endpoint, 7.6-point HAM-A improvement vs placebo","bullets":["MM-120 100 µg achieved 21.3-point HAM-A reduction vs 13.7 placebo (p=0.0004, Cohen's d=0.88) at Week 4 after single dose.","Clinical response rate 78% (100/200 µg) and remission 50% (100 µg) at Week 4; CGI-S improved from 'markedly ill' to 'borderline'.","Well-tolerated with mostly mild-moderate AEs on dosing day; 97.5% completion in high-dose groups with no AE discontinuations.","Plans End-of-Phase 2 meeting with FDA in H1 2024 and initiation of Phase 3 program in H2 2024; 12-week data expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294936","json":"https://secwatch.observer/filing/0001193125-23-294936.json","markdown":"https://secwatch.observer/filing/0001193125-23-294936.md","text":"https://secwatch.observer/filing/0001193125-23-294936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/0001193125-23-294936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/d605082d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:59:10.783566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}